In 2015, Xu et al. reported that elevated IL-18 together with IL-1b were significantly associated with advanced RCC stages, an elevated recurrence rate, and a shortened survival period among patients with localized RCC [35]. This evidence concerns the gene IL1B and renal cell carcinoma.